Spun out of the University of Washington Pacific Biomarkers, Inc, formerly known as Pacific Biometrics, was originally focused on lipids -providing specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. In 1994 Merchant House Scientific (cholesterol diagnostics) merged with Pacific Biometrics via a stock swap and preceding the firm's Public Offering in 1996. At the time, the firm was organizid around cardiovascular and osteoporosis diagnsotic products and laboratory services. Curently, Pacific Biomarkers offers biomarker testing services to pharmaceutical, biotech and in-vitro diagnostic (IVD) manufacturing companies through preclinical and Phase I-IV studies of drug and IVD development. Pacific Biomarkers provides accurate, reliable analyses, and responsive service to sponsors and investigative sites. Pacific Biomarkers collaborates with sponsors to develop, validate, improve analytical methods, and provide technical consultation for protocol design and provdes customized, project specific basis with the flexibity to meet clientneeds. In November 2018, Pacific Biomarkers acquired by Ampersand Capital Partners.
